Diffusion Efficiency and Bioavailability of Resveratrol Administered to Rat Brain by Different Routes: Therapeutic Implications

Neurotherapeutics

Volumn 12, Issue 2, 2015, Pages 491-501

  Shu, Xiao Hong ^a   Wang, Li Li ^a   Li, Hong ^a   Song, Xue ^a   Shi, Shun ^a   Gu, Jia Yao ^a   Wu, Mo Li ^a   Chen, Xiao Yan ^a   Kong, Qing You ^a   Liu, Jia ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

bioavailability; blood brain barrier; drug administration; glioblastoma neurotherapeutics; Resveratrol

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCURONOSYLTRANSFERASE; RESVERATROL; STILBENE DERIVATIVE;

ANALYSIS OF VARIANCE; ANIMAL; BRAIN; BRAIN NEOPLASMS; CELL SURVIVAL; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GLIOBLASTOMA; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; ANTICARCINOGENIC AGENTS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLUCURONOSYLTRANSFERASE; MALE; RATS; RATS, SPRAGUE-DAWLEY; STILBENES;

EID: 84939983287     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0334-6     Document Type: Article

References (42)

1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218–20.
2. Mancuso R, del Valle J, Modol L, Martinez A, Granado-Serrano AB, Ramirez-Núñez O, et al. Resveratrol improves motoneuron function and extends survival in SOD1 (G93A) ALS mice. Neurotherapeutics 2014;11:419–32.
3. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337–42.
4. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132: 257–60.
5. Sangeetha MK, Vallabi DE, Sali VK, Thanka J, Vasanthi HR. Sub-acute toxicity profile of a modified resveratrol supplement. Food Chem Toxicol 2013;59:492–500.
6. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 2002; 958: 439–47.
7. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann N Y Acad Sci 2011; 1215: 161–9.
8. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci 2011; 1215: 9–15.
9. Juan ME, Maijó M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal 2010; 51: 391–8.
10. Das S, Lin HS, Ho PC, Ng KY. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008; 25:2593–600.
11. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003–11.
12. Burkhardt JK, Riina HA, Shin BJ, Moliterno JA, Hofstetter CP, Boockvar JA. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011; 17: 286–95.
13. Figueiredo EG, Faria JW, Teixeira MJ. Treatment of recurrent glioblastoma with intra-arterial BCNU [1, 3-bis (2-chloroethyl)-1- nitrosourea]. Arq Neuropsiquiatr 2010; 68: 778–82.
14. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest New Drugs 2004; 22: 27–37.
15. Seigers R, Schagen SB, Van Tellingen O, Dietrich J. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 2013; 7: 453–9.
16. Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010; 255: 415–25.
17. Shu XH, Li H, Sun XX, Wang Q, Sun Z, Wu ML, et al. Metabolic patterns and biotransformation activities of resveratrol in human glioblastoma cells: relevance with therapeutic efficacies. PLoS ONE 2011; 6: e27484.
18. Sun Z, Shi S, Li H, Shu XH, Chen XY, Kong QY, et al. Evaluation of resveratrol sensitivities and metabolic patterns in human and rat glioblastoma cells. Cancer Chemother Pharmacol 2013; 72: 965–73.
19. Valable S, Lemasson B, Farion R, Beaumont M, Segebarth C, Remy C, et al. Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study. NMR Biomed 2008;21:1043–56.
20. Gu YT, Xue YX, Wang YF, Wang JH, Chen X, Shangguan QR, et al. Minoxidil sulfate induced the increase in blood-brain tumor barrier permeability through ROS/RhoA/PI3K/PKB signaling pathway. Neuropharmacology 2013;75:407–15.
21. Loch-Neckel G, Nemen D, Puhl AC, Fernandes D, Stimamiglio MA, Alvarez Silva M, et al. Stealth and non-stealth nanocapsules, containing camptothecin: in-vitro and in-vivo activity on B16-F10 melanoma. J Pharm Pharmacol 2007;59:1359–64.
22. Bock KW, Köhle C. UDP-glucuronosyltransferase 1A6: structural, functional, and regulatory aspects. Methods Enzymol 2005; 400: 57–75.
23. Heydel JM, Holsztynska EJ, Legendre A, Thiebaud N, Artur Y, Le Bon AM. UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation, and function. Drug Metab Rev 2010; 42: 74–97.
24. Emlia Juan M, Buenafuente J, Casals I, Planas JM. Plasmatic levels of trans-resveratrol in rats. Food Res International 2002;35:195–9.
25. Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate. Cell 2014;157:65–75.
26. Ates O, Cayli SR, Yucel N, Altinoz E, Kocak A, Durak MA, et al. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J Clin Neurosci 2007;14:256–60.
27. Hall ED, Vaishnav RA, Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010;7:51–61.
28. Ates O, Cayli S, Altinoz E, Gurses I, Yucel N, Sener M, et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem 2007;294:137–44.
29. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010;5:e15627.
30. Roy P, Kalra N, Prasad S, George J, Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009;26:211–7.
31. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–83.
32. Sun Z, Li H, Shu XH, Shi H, Chen XY, Kong QY, et al. Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells. FEBS J 2012;279:2381–92.
33. Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targeting with surface-modified poly (D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 2011;77:84–8.
34. De la Calle JL, Paíno CL. A procedure for direct lumbar puncture in rats. Brain Res Bull 2002;59:245–50.
35. Bullard DE, Bigner SH, Bigner DD. Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. Cancer Res 1985;45:5240–45.
36. Wright BL, Lai JT, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol 2012;259:1530–45.
37. Lavi R, Rowe JM, Avivi I. Lumbar puncture: it is time to change the needle. Eur Neurol 2010;64:108–13.
38. Zhang F, Shi JS, Zhou H, Wilson B, Hong JS, Gao HM. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol 2010;78:466–77.
39. Fukui M, Choi HJ, Zhu BT. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 2010;49:800–13.
40. Gao S, Hu M. Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem 2010;10:550–67.
41. Ceaglio N, Orozco G, Etcheverrigaray M, Mattio M, Kratje R, Perotti N, et al. High performance collection of cerebrospinal fluid in rats: evaluation of erythropoietin penetration after osmotic opening of the blood-brain barrier. J Neurosci Methods 2013;219:70–5.
42. Mothe AJ, Bozkurt G, Catapano J, Zabojova J, Wang X, Keating A, et al. Intrathecal transplantation of stem cells by lumbar puncture for thoracic spinal cord injury in the rat. Spinal Cord 2011;49:967–73.